MD4161528T2 - Combinație de ruxolitinib cu INCB057643 pentru utilizarea în tratamentul neoplasmelor mieloproliferative - Google Patents

Combinație de ruxolitinib cu INCB057643 pentru utilizarea în tratamentul neoplasmelor mieloproliferative

Info

Publication number
MD4161528T2
MD4161528T2 MDE20230400T MDE20230400T MD4161528T2 MD 4161528 T2 MD4161528 T2 MD 4161528T2 MD E20230400 T MDE20230400 T MD E20230400T MD E20230400 T MDE20230400 T MD E20230400T MD 4161528 T2 MD4161528 T2 MD 4161528T2
Authority
MD
Moldova
Prior art keywords
combination
ruxolitinib
treatment
incb057643
myeloproliferative neoplasms
Prior art date
Application number
MDE20230400T
Other languages
English (en)
Romanian (ro)
Inventor
Matthew Stubbs
Phillip C Liu
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of MD4161528T2 publication Critical patent/MD4161528T2/ro

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/5381,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MDE20230400T 2020-06-03 2020-09-14 Combinație de ruxolitinib cu INCB057643 pentru utilizarea în tratamentul neoplasmelor mieloproliferative MD4161528T2 (ro)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063034214P 2020-06-03 2020-06-03
PCT/US2020/050753 WO2021247064A1 (en) 2020-06-03 2020-09-14 Combination of ruxolitinib with incb057643 for treatment of myeloproliferative neoplasms

Publications (1)

Publication Number Publication Date
MD4161528T2 true MD4161528T2 (ro) 2026-03-31

Family

ID=72659928

Family Applications (1)

Application Number Title Priority Date Filing Date
MDE20230400T MD4161528T2 (ro) 2020-06-03 2020-09-14 Combinație de ruxolitinib cu INCB057643 pentru utilizarea în tratamentul neoplasmelor mieloproliferative

Country Status (23)

Country Link
EP (2) EP4161528B1 (https=)
JP (2) JP7669396B2 (https=)
KR (1) KR20230031242A (https=)
CN (1) CN115835868A (https=)
AU (1) AU2020451061A1 (https=)
CA (1) CA3184633A1 (https=)
CL (1) CL2022003409A1 (https=)
DK (1) DK4161528T3 (https=)
ES (1) ES3058891T3 (https=)
FI (1) FI4161528T3 (https=)
HR (1) HRP20251457T1 (https=)
IL (1) IL298200A (https=)
LT (1) LT4161528T (https=)
MA (1) MA59868B1 (https=)
MD (1) MD4161528T2 (https=)
MX (1) MX2022015220A (https=)
PH (1) PH12022553276A1 (https=)
PL (1) PL4161528T3 (https=)
PT (1) PT4161528T (https=)
RS (1) RS67440B1 (https=)
SI (1) SI4161528T1 (https=)
SM (1) SMT202600021T1 (https=)
WO (1) WO2021247064A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023009858A (es) * 2021-02-25 2023-09-12 Impact Biomedicines Inc Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis.
WO2024039883A2 (en) * 2022-08-19 2024-02-22 Translational Drug Development Llc Compositions and methods to treat myeloproliferative disorders and myeloproliferative neoplasms
AU2024306742A1 (en) * 2023-06-28 2025-12-04 Active Biotech Ab Quinoline carboxamides for use in the treatment of mpn

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100786927B1 (ko) 2000-06-28 2007-12-17 스미스클라인비이참피이엘시이 습식 분쇄방법
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제(R)―3―(4―(7H―피롤로[2,3-d]피리미딘―4―일)―1H―피라졸―1―일)―3―사이클로펜틸프로판니트릴의 염
PL3134403T3 (pl) * 2014-04-23 2020-07-13 Incyte Corporation 1H-pirolo[2,3-c]pirydyn-7(6H)-ony i pirazolo[3,4-c]pirydyn-7(6H)-ony jako inhibitory białek BET
CA3028689A1 (en) 2016-06-20 2017-12-28 Incyte Corporation Crystalline solid forms of a bet inhibitor

Also Published As

Publication number Publication date
IL298200A (en) 2023-01-01
LT4161528T (lt) 2026-02-10
SI4161528T1 (sl) 2026-01-30
EP4691563A2 (en) 2026-02-11
JP2023529365A (ja) 2023-07-10
PH12022553276A1 (en) 2024-02-19
EP4161528A1 (en) 2023-04-12
JP7669396B2 (ja) 2025-04-28
CN115835868A (zh) 2023-03-21
FI4161528T3 (fi) 2025-12-12
MX2022015220A (es) 2023-03-08
WO2021247064A1 (en) 2021-12-09
RS67440B1 (sr) 2025-12-31
DK4161528T3 (da) 2025-11-24
HRP20251457T1 (hr) 2026-01-02
PT4161528T (pt) 2026-01-23
SMT202600021T1 (it) 2026-03-09
CL2022003409A1 (es) 2023-05-26
ES3058891T3 (en) 2026-03-13
AU2020451061A1 (en) 2022-12-15
CA3184633A1 (en) 2021-12-09
EP4691563A3 (en) 2026-04-01
KR20230031242A (ko) 2023-03-07
JP2025111539A (ja) 2025-07-30
PL4161528T3 (pl) 2026-03-16
MA59868B1 (fr) 2025-11-28
EP4161528B1 (en) 2025-11-05

Similar Documents

Publication Publication Date Title
MD4161528T2 (ro) Combinație de ruxolitinib cu INCB057643 pentru utilizarea în tratamentul neoplasmelor mieloproliferative
BR0313461A (pt) Novas imidazopiridinas e respectivo uso das mesmas
PE20050123A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas y composiciones farmaceuticas que los incluyen
ATE327756T1 (de) Verwendung von cgmp-phosphodiesterase hemmer zur behandlung von impotenz
ATE546143T1 (de) Mittel zur behandlung von glaukom mit einem rho- kinase-hemmer und prostaglandinen
BRPI0407827B8 (pt) compostos de aminoeteroarila como inibidores de proteína cinase e respectivos usos
BR0308407A (pt) Compostos de quinazolina úteis em terapia
UY23893A1 (es) Derivados tetraciclicos, procedimiento de preparación y uso
ATE325094T1 (de) Sulfonamide enthaltende indolderivate
ECSP055964A (es) Heterociclil-3-sulfonilindazoles como ligandos de 5-hidroxitriptamina-6
IS5352A (is) Ný efnasambönd
AR041942A1 (es) Derivados de 10-oxa -1-aza-dibenzo [a,d] ciclohepteno-7-carboxilico como antagonistas ccr1 para el tratamiento de la enfermedad desmielinizante inflamatoria
BR0010072A (pt) 1-amino triazolo[4,3-a] quinazolina-5-onas e/ou -5-tionas inibidoras de fosfodiesterases iv
BR0010693A (pt) Derivados azaindol para tratamento de depressão
SE9702563D0 (sv) Compounds
PA8525801A1 (es) Compuestos de pirazol, composiciones farmacéuticas, y métodos para modular y/o inhibir la actividad de erab/hadh2
MX2023000084A (es) Derivados de 10-(di(fenil)metil)-4-hidroxi-8,9,9a,10-tetrahidro-7h -pirrolo[1',2':4,5]pirazino[1,2-b]piridazina-3,5-diona y compuestos relacionados como inhibidores de la replicacion del ortomixovirus para el tratamiento de influenza.
ATE383356T1 (de) Piperazinbenzothiazole als wirkstoffe in der behandlung von ischämien und krankheiten des zns- systems
DE69116788D1 (de) 4-substituierte Dihydropyrido [4,3-d] pyrimidine als Analgetika und entzündungshemmende Mittel zur topischen Anwendung bei der Behandlung von Hauterkrankungen
AR036124A1 (es) Empleo de derivados de acidos 2,5-dihidroxibencenosulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil
ATE297926T1 (de) Hexahydropyrazino(1'2':1,6)-pyrido(3,4-b)indole 1,4-dion-derivate zur behandlung von cardiovaskulären erkrankungen und erektionsstörungen
ATE192040T1 (de) Wirkstoff gegen arteriosklerose
DK470686D0 (da) Pyrimidinderivater
AR057061A1 (es) Espiro-bencimidazoles farmaceuticamente activos y su uso en la fabricacion de medicamentos
BR0311138A (pt) Produto combinado, método de preparação do mesmo, kit de partes, método de tratamento de arritmia, e, usos de um produto combinado e de um composto